rs1142345

rs1142345 is a specific single nucleotide polymorphism (SNP) located in the genetics of humans. It is identified by its reference SNP cluster ID (rsID) in the dbSNP database, which is maintained by the National Center for Biotechnology Information (NCBI). The rs1142345 variant involves a change in a single nucleotide base within a specific gene, influencing genetic variation among individuals.

This SNP is notably associated with the CYP2C19 gene, which encodes an enzyme that plays a crucial role in the metabolism of various drugs, including proton pump inhibitors, antiplatelet agents, and certain antidepressants. Variants in CYP2C19, including rs1142345, can affect enzymatic activity, leading to differences in drug efficacy and the risk of adverse reactions. Such pharmacogenetic implications make rs1142345 an important marker in personalized medicine.

The allele frequency of rs1142345 varies among different populations and ethnic groups, which can influence the prevalence of certain metabolic phenotypes, such as poor or rapid metabolizers. Understanding an individual's rs1142345 genotype can be valuable in tailored drug dosing and treatment strategies.

Research into rs1142345 continues to explore its broader implications, including its potential links to disease susceptibility and drug response variability. As with other genetic markers, the interpretation of rs1142345 requires comprehensive genetic analysis and consideration of other variants within the genome.

In summary, rs1142345 is a significant genetic variant within the CYP2C19 gene, impacting drug metabolism and personalized treatment approaches. Its study contributes to the growing field of pharmacogenomics and individualized healthcare solutions.